Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Authors:
- 1 November 2007
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (suppl 3) , iii2-iii22
Abstract
The perspective of this consensus is from the treating physician’s point of view.Keywords
This publication has 442 references indexed in Scilit:
- Rituximab-induced long-term remission in two children with SLEEuropean Journal of Pediatrics, 2006
- Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Care & Research, 2005
- Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapyArthritis & Rheumatism, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot studyJournal of Hepatology, 2002
- Remission of Behçet's syndrome with TNFα blocking treatmentAnnals of the Rheumatic Diseases, 2002
- Etanercept in graft-versus-host diseaseBone Marrow Transplantation, 2000
- InfliximabDrugs, 2000
- EtanerceptDrugs, 1999